{"id":"d-2570","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5946498","moleculeType":null,"molecularWeight":"528.98"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K/AKT pathway, D-2570 aims to reduce cancer cell proliferation and induce apoptosis. This mechanism is being explored in the treatment of various cancers.","oneSentence":"D-2570 is a small molecule that targets the PI3K/AKT pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:36.520Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07489885","phase":"PHASE2","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-05","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT07411742","phase":"PHASE1","title":"Mass Balance Study of [14C] D-2570","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-03-04","conditions":"Mass Balance Study","enrollment":8},{"nctId":"NCT07326813","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-01-13","conditions":"Plaque Psoriasis","enrollment":477},{"nctId":"NCT07311200","phase":"PHASE2","title":"A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-01-15","conditions":"Active Systemic Lupus Erythematosus","enrollment":120},{"nctId":"NCT07315061","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2025-12-22","conditions":"PsA (Psoriatic Arthritis)","enrollment":222},{"nctId":"NCT07270783","phase":"PHASE1","title":"Healthy Volunteer Study","status":"RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2025-12-04","conditions":"Healthy Volunteer","enrollment":36},{"nctId":"NCT07275775","phase":"PHASE1","title":"Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2024-08-13","conditions":"Healthy","enrollment":100},{"nctId":"NCT06278350","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2024-01-31","conditions":"Plaque Psoriasis","enrollment":161},{"nctId":"NCT07130604","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2025-09-18","conditions":"Plaque Psoriasis","enrollment":390},{"nctId":"NCT07035041","phase":"PHASE2","title":"A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2025-05-22","conditions":"UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D-2570","genericName":"D-2570","companyName":"InventisBio Co., Ltd","companyId":"inventisbio-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D-2570 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}